Analystreport

Horizon Therapeutics PLC (NASDAQ: HZNP) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $45.00 price target on the stock.

Horizon Therapeutics Public Limited Company - Ordinary Shares  (HZNP) 
Last horizon therapeutics public limited company - ordinary shares earnings: 2/26 07:00 am Check Earnings Report